opticology

Opticology Moves Operations to New Brooklyn NY Facility

Tue, 17 Nov 2020 19:00:53 GMT

Located in the waterfront manufacturing district and leading to increased manufacturing capabilities for Opticology.

Opticology, Inc. has acquired a new facility in Brooklyn New York in the waterfront manufacturing district known as Redhook. The century old buildings are being renovated to include design offices and state-of-art optical laboratories for optical test, measurement, and assembly. The new space will include an area dedicated to manufacturing of optical and mechanical components as well as a prototyping shop.

The company expects the expansion to provide higher capacity in the assembly of precision optical systems and subassemblies for its OEM customers that are demanding higher volumes at lower cost. “The new space also allows us to take on additional contractual development work of unique optical systems which has been a big part of who we are”, says Tony Cappo, Principal Engineer.

Increased manufacturing capabilities include optical processing equipment which will provide better control over multifaceted projects and will improve delivery times. Several pieces of new equipment are being slated for purchase as the new facility comes online.

Opticology, Inc. designs and engineers custom optical systems for research, industrial, and medical device customers. Opticology builds custom optical devices and delivers complete assemblies in prototype and production quantities.

Opticology Research Files Patent For Field Portable Detection Device

Mon, 20 Jan 2020 16:09:00 GMT

The company announced today the filing of an important patent as a result of the work of its research business unit of a field portable system for the detection of chemical and biological agents. Principal Engineer Anthony Cappo comments "We are considered experts in the field of custom surface plasmon resonance (SPR) instruments and in particular miniaturized units. Our clients have expressed a need for a field portable version of the technology that can be used in hostile environments and our latest technology developments fits that bill."

The company intends to commercialize the field-portable sensor platform for a host of detection modalities including heavy metals, residual explosives, or infectious disease that can be measured with precision without the need for laboratory analysis.

Opticology Inc. Marks Its 20th Year In Business With The Coming Of The New Year.

Tue, 29 Jan 2019 17:35:47 GMT

Opticology celebrates 20 years of successfully serving customers in optical design, engineering, and fabrication. Established in January 1999, the company has evolved as one of the leading service provider for outsourced optical engineering and design. Providing fabrication and prototype building services is an essential part of the business and important and necessary to customers in R&D and product development. Entrenched in the industry, Opticology also supplies optical and mechanical components on an OEM basis with the same level of service. Customers primarily consist of large corporations in the fields of medical device and industrial systems.

Following its original mission of exemplary service, the tradition lives on. "There are lots of folks out there providing design or with the machinery to produce precision optics." says Tony Cappo, Principal Optical Engineer. "But without good service - knowing you will get efficient and elegant design, get you parts on time, or clever solutions when there is a problem - it is virtually worthless. We always strive for good engineering and good communication with the customer whether it is designing a part or system or supplying volume components. Our customers don't like surprises and neither do we."

And what is in store for future? "Opticology has remained very close knit and stayed small so we can properly serve existing clients, be selective on the work we choose to do, and maintain our R&D projects and support our spin off companies." There has been talk of casting a wider net and accepting more commercial clients steering away from R&D. "We'll see." says Cappo.

Prospective clients can contact Tony Cappo directly at tcappo@opticology.com or 212-243-4328.

Opticology Inc. will exhibit at SPIE BiOS 2018, a biomedical optics conference preceding SPIE Photonics West.

Fri, 19 Jan 2018 07:00:00 GMT

The company intends to showcase its abilities as a contract developer of medical and scientific instruments.

Work samples of prototype devices will be on hand as will some of the OEM components it builds for its design clients.

In addition to Opticology's core contract business, the company will also have on display work from its internal development business Opticology Research which is the development arm of the company which has spun off four companies in the medical device and environmental testing fields.

To learn more, visit: https://spie.org/exhibitor/details.aspx?expo=SPIE-BiOS-2018&name=Opticology%2c-Inc.-New-York-NY&

Opticology Inc. Will Exhibit at SPIE BiOS

Sat, 07 Jan 2017 07:00:00 GMT

The largest biophotonics, biomedical optics, and imaging conference.

Opticology Inc. will exhibit at SPIE BiOS 2017, a biomedical optics conference preceding SPIE Photonics West.

The company intends to showcase its abilities as a contract developer of medical and scientific instruments. Work samples of prototype devices will be on hand as will some of the OEM components it builds for its design clients.

See Opticology, Inc., and Opticology Research including sister companies Tear Glucose Research, Centrofuse Technologies, Lacrisciences, and SPR Technologies at SPIE BiOS, 28 January-2 February 2017, The Moscone

Center, San Francisco CA, Space #8454

To learn more, visit: https://spie.org/exhibitor/details.aspx?expo=SPIE-BiOS-2018&name=Opticology%2c-Inc.-New-York-NY&

Opticology's Affiliate Tear Glucose Research Featured in National Institute for Health Research (UK) Horizon Scanning Review

Mon, 16 May 2016 15:58:58 GMT

"New and Emerging Non-Invasive Glucose Monitoring Technologies"

Tear Glucose Research (TGR), a spin off company of Opticology, Inc. is named as one of 40 companies identified developing non-invasive glucose monitoring technology to replace finger-stick blood glucose meter currently used by millions who suffer from diabetes. Other companies named in the report include big players Abbott Diabetes Care, Novartis Alcon (Google), and Freedom Meditech.

TGR uses an optical technique, surface plasmon resonance, to measure glucose concentrations in the ocular tears which are known to track blood glucose levels in the body. The device is in the form of a small pen-shaped probe with a small tip sensitized with proprietary glucose sensing chemistry.

Read more about it, here: https://www.researchgate.net/publication/315070338_New_and_emerging_non-invasive_glucose_monitoring_technologies

Opticology Registers for International Traffic in Arms Regulations (ITAR)

Wed, 07 Oct 2015 07:00:00 GMT

In an effort to continue its broad appeal to clients in various industries, Opticology, Inc. has completed registration

for ITAR through the US Department of State Office of Defense Trade Controls Compliance. ITAR registration is required for companies engaged in manufacturing or exporting defense articles or services pursuant to the Arms Export Control Act.

Visit The International Traffic in Arms Regulations (ITAR) website for more information.

https://www.pmddtc.state.gov/ddtc_public?id=ddtc_public_portal_itar_landing

Opticology Founder Featured in Crain's New York Business for Work on Tear Glucose

Tue, 05 Aug 2014 07:00:00 GMT

Tear Glucose Research, LLC, a biotechnology company spun out of Opticology, Inc. is featured in Crain's New York Business. In the article "Six biotech startups to watch", the company and its founder are featured for the development of a hand held sensing probe to measure the amount of glucose in human tears, a direct correlation to blood glucose.

Read The Full Story Here: https://www.crainsnewyork.com/article/20140805/HEALTH_CARE/308039987/device-offers-less-pain-for-diabetics

Team Wins Funding from New York City Economic Development Corporation for Tear Glucose Studies

Thu, 27 Jun 2013 07:00:00 GMT

Big Things Are Happening In The Medical Field.

Opticology, Inc. and the New York Eye & Ear Infirmary have been awarded funding for continued development of a diagnostic device for measuring glucose levels in the human tear film. The device has the potential to replace or supplement current finger-prick blood glucose meter used by diabetics, without the pain and inconvenience of drawing blood. Tear glucose can be measured with a gentle touch just above the lower eyelid with a small, portable, pen shaped device.

With the funding, the team will have the opportunity to conduct a clinical study of their handheld device and glucose sensitive chemistry which is attached to the device tip. The award was granted under a New York City Economic Development Corporation initiative PILOT Health Tech NYC.

Opticology Principals to Present at 2013 ARVO Annual Meeting

Thu, 21 Feb 2013 07:00:00 GMT

In partnership with New York Eye & Ear Infirmary and the Lighthouse International, both of New York, Opticology principals Anthony Cappo and Matthew Orr will present their findings from a clinical study entitled A New Method to Depict Central Scotomas: Automated Stereocampimetry at the 2013 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle this coming May.

Opticology has worked closely with medical researchers in the development of this new device which can measure with precision pathological areas of non-vision on the retina, or scotomas, typically found in patients with age-related macular degeneration or diabetic retinopathy. The device consists of minimal hardware, controlled by software and is installed compactly on modern ophthalmic examination chair swing arm. It is meant to be a low cost alternative yet provide valuable information to the clinician regarding diagnosis and following disease after treatment.

Additional Tear Diagnostic Patent Issues

Tue, 21 Aug 2012 07:00:00 GMT

Patent Issued for Opticology.

Opticology announced today the issuance of US Patent # 8,249,682 describing a device for measuring concentrations of constituents in tear samples. Long time colleagues Anthony Cappo and Diptabhas Sarkar have spun out a company to commercialize the device for measuring glucose in human tears as an alternative to monitoring blood glucose through finger pricks.

The patent is also being applied toward detection of dye eye syndrome, proteins, viruses, bacteria and other constituents that manifest in the ocular tear film.

Opticology Offshoot Receives Notice of Allowance of Important Patent

Sat, 12 May 2012 07:00:00 GMT

Patent Issued To Tear Glucose Research, LLC.

Opticology announced today that a key US patent for one of its spin-off companies has received a Notice of Allowance from the US patent office. Opticology principal Anthony P. Cappo is primary inventor on the patent which focusses on non-invasive diagnostics via the ocular tear film. Opticology is involved in the development of a new device to measure glucose concentrations in ocular tears as a non-invasive means of determining blood glucose without drawing blood.

The spin-off company, Tear Glucose Research, LLC, has an exclusive license to the patent for glucose determination in tears. The company is developing a novel biosensor and the accompanying handheld device which promises to be a convenient and painless means to measure blood glucose in diabetics.

Opticology Spins off Non-Invasive Glucose Co.

Sat, 17 Apr 2010 07:00:00 GMT

New device available to measure glucose levels in human tears.

Principals at Opticology have formed a company to commercialize a new device for measuring glucose concentrations in human tears. The patented technology developed internally at Opticology, is intended as a means to non-invasively measure blood sugar in diabetics. The new company, Tear Glucose Research, LLC, is in cooperation with a university chemistry laboratory and a research hospital. The company is developing a highly sensitive glucose-specific ligand for direct detection of glucose levels in the body via ocular tears.

Principal Engineer Awarded Broad Patent for Human Tear Diagnostics

Fri, 01 Aug 2008 07:00:00 GMT

Anthony P. Cappo, Principal Optical Engineer at Opticology, Inc., is the primary inventor on US Patent #7,395,103 which issued July 2008. The patent provides broad protection for a handheld portable probe employing Surface Plasmon Resonance Spectroscopy to directly probe the human tear film. Worldwide patents are pending.

Opticology Principals Ophthalmic Device Patent Issues

Fri, 21 Dec 2007 07:00:00 GMT

A key patent in ophthalmic diagnostics issued December 18th. Opticology principals Anthony Cappo and Matthew Orr are key inventors to technology used to measure areas of non-vision in cases of diabetic retinopathy and age-related macular degeneration.

The patent has been assigned to Centrofuse Technologies, LLC.

Tear Diagnostics Moves Towards Commercial Development

Tue, 03 Apr 2007 07:00:00 GMT

Opticology announced today that it has assigned its rights and interest to a patent application related to dry eye diagnostics to a new company aptly named LacriSciences, LLC. The new company will focus on commercial development of a direct probing osmometer for detection of dry eye. The company plans to explore using the device for other means of disease detection that manifest in the tear film including bacterial and viral infections.

The company was formed in partnership with world renowned expert on dry eye and the ocular tear film Jeffrey P. Gilbard, MD. Dr. Gilbard was the first to develop tear osmolarity as a diagnostic test in 1976, and is the Founder, CEO and Chief Scientific Officer of Advanced Vision Research, makers of TheraTears. Opticology will continue to participate in the early stage design and development of the device.